Clobetasol Propionate, 0.05%, vs Hydrocortisone, 1%, for Alopecia Areata in Children: A Randomized Clinical Trial

• Autores: Patsy Lenane, Colin Macarthur, Patricia C. Parkin, Bernice Krafchik, Julie DeGroot
• Localización: JAMA Dermatology, ISSN 2168-6068, Vol. 150, Nº. 1, 2014, págs. 47-50
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Importance Alopecia areata is an idiopathic cause of hair loss with limited therapeutic repertoire.

    Objective To compare the efficacy and safety of a high- vs low-potency topical corticosteroid in pediatric patients.

    Design, Setting, and Participants This single-center, randomized, blind, 2-arm, parallel-group, superiority trial was carried out over a 24-week period at a tertiary referral academic dermatology clinic at The Hospital for Sick Children in Toronto, Ontario, Canada. Forty-two children attending the outpatients clinic, 2 to 16 years of age with alopecia areata affecting at least 10% of scalp surface area, were eligible; 1 declined to participate. There were no withdrawals from the study.

    Interventions for Clinical Trials Patients were randomly assigned to receive clobetasol propionate, 0.05% cream, or hydrocortisone, 1%, cream. Patients applied a thin layer of the assigned cream twice daily to the areas of hair loss for 2 cycles of 6 weeks on, 6 weeks off, for a total of 24 weeks.

    Main Outcomes and Measures The primary outcome was the change in scalp surface area with hair loss over 24 weeks following enrollment.

    Results All participants were assessed at 6, 12, 18, and 24 weeks (except 1 participant who missed the 6-week visit). After adjusting for baseline hair loss, the clobetasol group had a statistically significant (P?

    Conclusions and Relevance Topical clobetasol propionate, 0.05%, cream is efficacious and safe as a first-line agent for limited patchy childhood alopecia areata.